01:46 PM EDT, 04/08/2024 (MT Newswires) -- CorMedix ( CRMD ) said Monday it entered a five-year agreement to supply its DefenCath product to Florida-based dialysis organization ARC Dialysis.
DefenCath was approved in the US in November 2023 and CorMedix ( CRMD ) plans to commercialize the product in the inpatient setting starting April 15.
Price: 4.73, Change: +0.02, Percent Change: +0.42